Premium
Nitric oxide in patients with transitional bladder cancer
Author(s) -
Eiján Ana María,
Piccardo Inés,
Riveros María Doris,
Sandes Eduardo Omar,
Porcella Hugo,
Jasnis María Adela,
Sacerdote De Lustig Eugenia,
Malagrino Hector,
Pasik Leonardo,
Casabé Alberto Ricardo
Publication year - 2002
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.10170
Subject(s) - medicine , urine , bladder cancer , urology , creatinine , nitric oxide , nitric oxide synthase , transitional cell carcinoma , griess test , urinary system , urinary bladder , cancer , gastroenterology , pathology , nitrite , biology , ecology , nitrate
Background and Objectives One of the current challenges in clinical oncology is the identification of patients with superficial transitional bladder carcinoma (TBC) at high risk of recurrence or myoinvasive disease. Recently, inducible nitric oxide synthase (iNOS) expression was detected in urinary bladder cancers. Because iNOS produces a high concentration of nitric oxide (NO), we thought it possible that urine from TBC patients produces high levels of NO. The aim of this study was to determine urine NO levels in TBC compared with healthy controls and with patients bearing other nonrelated tumors, as well as to examine iNOS expression in bladder cancer tissue. Methods This study evaluated patients with TBC (n = 33), with gynecological tumors (GT) (n = 19), TBC patients with no evidence of tumor (no evidence of disease [NED]) (n = 19), and healthy subjects (n = 39). Urine NO levels were determined by Griess reagent, expressed as μM NO 2 − /100 mg creatinine. Results TBC patients produced significantly higher urine NO median values (4.2 μM; range, 2.1–91.6) than were produced by healthy individuals (2.1 μM; range, 0.4–4.9), by the NED group (1.7 μM; range 1.2–5.4), and by GT patients (2.0 μM; range, 0.8–58.1) ( P = 0.000, Kruskal‐Wallis test). iNOS was detected by Western blot in 52% (13/25) of bladder tumors examined. Conclusions Although a wider study is necessary, our results suggest that the enhanced NO levels could perhaps be considered as a putative marker in TBC patients. J. Surg. Oncol. 2002;81:203–208. © 2002 Wiley‐Liss, Inc.